Quick Answer
Anika Therapeutics, Inc. reported Operating Income Loss of -$11.05 million for the year ending 2025.
- Anika Therapeutics, Inc. showed a decrease of -116.6% in Operating Income Loss from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $2.08 million | Q1 2011: $556.7 thousand | Q2 2011: $3.68 million | Q3 2011: $4.82 million | Q1 2012: $3.06 million | Q2 2012: $6.13 million | Q3 2012: $2.73 million | Q1 2013: $5.01 million | Q2 2013: $9.40 million | Q3 2013: $7.77 million | Q1 2014: $23.87 million | Q2 2014: $15.20 million | Q3 2014: $10.29 million | Q1 2015: $5.50 million | Q2 2015: $12.43 million | Q3 2015: $13.14 million | Q1 2016: $10.71 million | Q2 2016: $13.47 million | Q3 2016: $13.69 million | Q1 2017: $8.01 million | Q2 2017: $17.73 million | Q3 2017: $10.27 million | Q1 2018: -$7.83 million | Q2 2018: $11.25 million | Q3 2018: $8.57 million | Q1 2019: $5.48 million | Q2 2019: $11.92 million | Q3 2019: $12.05 million | Q1 2020: $7.09 million | Q2 2020: -$9.54 million | Q3 2020: -$7.93 million | Q1 2021: $1.26 million | Q2 2021: $9.18 million | Q3 2021: $1.30 million | Q1 2022: -$3.55 million | Q2 2022: -$3.38 million | Q3 2022: -$5.80 million | Q1 2023: -$12.55 million | Q2 2023: -$3.63 million | Q3 2023: -$7.67 million | Q1 2024: -$2.51 million | Q2 2024: -$1.81 million | Q3 2024: -$81.0 thousand | Q1 2025: -$4.28 million | Q2 2025: -$4.18 million | Q3 2025: -$3.23 million.
- Over the full 17 years of available data (2009 to 2025), Anika Therapeutics, Inc.'s Operating Income Loss has declined by 297.8%.
- Historical annual values: Fiscal year 2025: -$11.05 million | Fiscal year 2024: -$5.10 million | Fiscal year 2023: $844.0 thousand | Fiscal year 2022: $3.67 million | Fiscal year 2021: $2.62 million | Fiscal year 2020: -$28.32 million | Fiscal year 2019: $34.25 million | Fiscal year 2018: $21.75 million | Fiscal year 2017: $45.73 million | Fiscal year 2016: $50.61 million | Fiscal year 2015: $48.13 million | Fiscal year 2014: $61.45 million | Fiscal year 2013: $32.61 million | Fiscal year 2012: $19.72 million | Fiscal year 2011: $13.97 million | Fiscal year 2010: $7.54 million | Fiscal year 2009: $5.59 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: